Scientific area
3.1 Basic medicine
Discipline(s)
Neurosciences (including psychophysiology)
Project title
Eslicarbazepine acetate - Epilepsy treatment in pediatric patients
Scientific Coordinator's name:
Prof. Patrício Soares-da-Silva
Scientific Coordinator's e-mail:
psoares.silva@bial.com
Principal R&D Unit:
Prof. Patrício Soares-da-Silva
Other R&D Units involved in the project:
Other R&D units involved in the project
Project keyword(s)
Eslicarbazepine acetate, Epilepsy, Pediatric, Adjunctive therapy
Short abstract and comments
BIAL – Portela & Cª, S.A. is performing a confirmatory phase III study to assess the efficacy and safety of eslicarbazepine Acetate as adjunctive therapy in children and adolescents with refractory partial epilepsy. As cognitive co-morbidity is of particular concern in children with epilepsy, due to the impact on learning and psychosocial interaction, a second pediatric study is being conducted in children and adolescents with refractory partial-onset seizures to assess the cognitive effects and safety of adjunctive eslicarbazepine acetate. Cognitive effects will be assessed using the UBC System, a validated cognitive test battery, and will be related to the developmental changes and disease progression occurring in the study population.
Potential uses/indications
Adjunctive therapy in pediatric patients
Status
Ongoing
Partner Status: Seeking Partners?
No
Grant number (QREN, FP7, Eureka, etc)
QREN 4859
Last edited on
2011-11-09 14:13:14